References
- KanodraNMPopeCHalbertCHSilvestriGARiceLJTannerNTPrimary care provider and patient perspectives on lung cancer screening. A qualitative studyAnn Am Thorac Soc201613111977198227676369
- HenschkeCIYipRSmithJPCT screening for lung cancer: part-solid nodules in baseline and annual repeat roundsAJR Am J Roentgenol201620761176118427726410
- DomvriKZarogoulidisPDarwicheKMolecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapyJ Cancer20134973675424312144
- ZarogoulidisKZarogoulidisPDarwicheKTreatment of non-small cell lung cancer (NSCLC)J Thorac Dis20135Suppl 4S389S39624102012
- StratakosGGerovasiliVDimitropoulosCSurvival and quality of life benefit after endoscopic management of malignant central airway obstructionJ Cancer20167779480227162537
- Hohenforst-SchmidtWZarogoulidisPPitsiouGDrug eluting stents for malignant airway obstruction: a critical review of the literatureJ Cancer20167437739026918052
- ZarogoulidisPGagaMHuangHDarwicheKRaptiAHohenforst-SchmidtWTissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?Clin Transl Med201761628101783
- PapadopoulouETsoulosNTsirigotiADetermination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patientsOncol Lett20151042172184
- ZaricBStojsicVKovacevicTClinical characteristics, tumor, node, metastasis status, and mutation rate in domain of epidermal growth factor receptor gene in Serbian patients with lung adenocar-cinomaJ Thorac Oncol2014991406141025122436
- Hohenforst-SchmidtWZarogoulidisPSteinheimerMTyrosine kinase inhibitors for the elderlyJ Cancer20167668769327076850
- YarmusLAkulianJGilbertCOptimizing endobronchial ultrasound for molecular analysis. How many passes are needed?Ann Am Thorac Soc201310663664324079724
- SoejimaKYasudaHHiranoTOsimertinib for EGFR T790M mutation-positive non-small cell lung cancerExpert Rev Clin Pharmacol2016101313827885838
- SperanzaGCohenVAgulnikJSMolecular changes in epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) biopsies at time of progression compared to initial biopsyJ Clin Oncol20092715 Supple22066
- MetroGRicciutiBBrambillaMThe safety of nivolumab for the treatment of advanced non-small cell lung cancerExpert Opin Drug Saf201616110110927910704
- BlumenscheinGJrChandlerJGaronEBPS01.59: CheckMate 370: a master protocol of phase 1/2 studies of nivolumab as maintenance or first-line +/− standard-of-care therapies in advanced NSCLC: Topic: Medical OncologyJ Thorac Oncol20161111SS307
- ValechaGKVennepureddyAIbrahimUSafaFSamraBAtallahJPAnti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapyExpert Rev Anticancer Ther2017171475927841044
- CoboMGutierrezVRodeloLLopezORuizMGodoyAAfatinib en pacientes con carcinoma de células escamosas de pulmón: contexto actual y la opción de tratamiento oral [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment]Med Clin [Barc]2016146Suppl 12529 Spanish
- KeatingGMAfatinib: a review in advanced non-small cell lung cancerTarget Oncol201611682583527873136
- Diz TainPGonzalezALGarcia-PalomoAMecanismo de acción y desarrollo preclínico de afatinib [Mechanism of action and preclinical development of afatinib]Med Clin [Barc]2016146Suppl 1711 Spanish
- YangJHeJYuMLiTLuoLLiuPThe efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)Medicine20169550e559927977596
- SantosFNCastriaTBCruzMRRieraRChemotherapy for advanced non-small cell lung cancer in the elderly populationSao Paulo Med J2016134546546627901246
- KomiyaKNakamuraTNakashimaCSPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancerOncoTargets Ther2016966636668